Targeted Therapy Trials: Approval Strategies, Target Validation, or Helping Patients?

This publication has 7 references indexed in Scilit:

• Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
  Journal of Clinical Oncology, 2007
• Molecular determination of epidermal growth factor receptor in normal and neoplastic colorectal mucosa
  British Journal of Cancer, 2006
• Assessment of epidermal growth factor receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis
  Cancer Biology & Therapy, 2005
• Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
  New England Journal of Medicine, 2004
• Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor
  Journal of Clinical Oncology, 2004
• FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study
  Journal of Clinical Oncology, 2004
• Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF‐κB and AP‐1 activation and IL‐8 and VEGF expression in human head and neck squamous cell carcinoma lines
  International Journal of Cancer, 2002